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Background: Mesothelin, a mesothelial marker, has been found expressed in and as a potential treatment target of
cholangioacarcinoma (CC). It is possible that CC may be derived from the cells sharing mesothelial markers.
However, the expression of other mesothelial markers in CC is largely unknown.
Methods: Thirty CC cases (10 extrahepatic and 20 intrahepatic) were retrieved from our institutional archive.
The immunohistochemical study of Calretinin (DC8), WT1 (6F-H2), Lymphatic Endothelial Marker (D2-40), CK5/6
(D5/16 B4) and CK19 (b170) was done on formalin fixed paraffin embedded sections for 2–3 blocks of each case.
We compared the expression levels between CC and normal bile duct (NBD) on the same block.
Results: All of the CC and NBD are positive for CK19 (23/23) and negative for WT1 (0/23) and D2-40 (0/23), except
one CC positive for D2-40(1/30, 3.3%) and one NBD positive for WT1 (1/23, 4.3%). Calretinin immunoreactivity was
detected in 52.2% (12/23) of CC, but none in NBD (0/23). CK5/6 was also detectable in 73.3% (22/30) of CC and all
NBD (30/30). Increased expression of calretinin and reduced expression of CK5/6 were more likely associated with
CC than NBD (P < 0.001 and P = 0.002, respectively). The sequential staining pattern of positive calretinin and
negative CK5/6 in calretinin negative cases has a sensitivity of 69.57% and a specificity of 100% for differentiating CC
from NBD. CK5/6 expression was also more likely associated with well-differentiated CC (7/7 versus 12/20 in moderately
differentiated, and 9/10 in poorly differentiated, P = 0.019) and extrahepatic CC (10/10 versus 12/20 in intrahepatic,
P = 0.029), but there was no association between the calretinin expression and the CC grade or location.
Conclusion: Calretinin and CK5/6 immunohistochemical stains may be useful for diagnosing a CC. Their
immunohistochemical results should be interpreted with caution in the cases with differential diagnoses of
mesothelioma and CC. A full mesothelioma panel, including WT1 and/or D2-40, is recommended to better define a
mesothelial lineage. The biology of calretinin and CK5/6 expression in CC is unclear, but might shed light on identifying
therapeutic targets for CC.
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Intrahepatic cholangiocarcinoma (CC) is a relatively rare
carcinoma of the biliary tree, with rising incidence and
mortality [1,2]. Its 1-, 2- and 5-year survivals in US are
24.5%, 11.8% and 3.2%, respectively [1]. The diagnosis
and prognostication of CC become critical for managing
those patients. Studies have shown that several immuno-
histochemical (IHC) markers are highly expressed in CC* Correspondence: pjz@mail.med.upenn.edu
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unless otherwise stated.including Annexin A1 (94.1%), CK19 (89%), MOC31
(88.2%), CK7 (83.4%), CD133 (79%), claudin4 (69.2%),
high mobility group A1 (HMGA1) (31.5%) and S100P
[3-6], while others has no or very low expression in CC
such as glypican 3 (GPC3) (7%) and biglycan (7%) [3].
However, the markers’ expression levels are rarely com-
pared with that of normal bile duct (NBD) which could
be a morphologic mimic for CC in small lesion or small
sampling. In addition to pancreatic carcinoma, a recent
study shows that mesothelin, a mesothelial marker, is
also found in 33% of resected CC specimens, but not
hepatocellular carcinoma (HCC) or normal liver tissue
[7]. Moreover, mesothelin may be used as a target forLtd. This is an Open Access article distributed under the terms of the Creative
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and as a prognostic factor for CC [8,9]. It is possible
that mesothelium related proteins and/or genes may
also be present in other tumors and involved in their
tumorigenesis. Indeed, mesothelin and calretinin are
found expressed in thymic carcinoma, thymoma, and
non-keratinizing squamous cell carcinoma of lung [10,11].
But little is known regarding the expression levels, if any,
of other mesothelial markers such as calretinin, CK5/6,
D2-40 and WT1. Hence, we aimed to examine the IHC
staining pattern of those markers in CC and NBD, and to
explore the potential “mesothelial” phenotype in CC. The
findings may help identify more diagnostic markers and
therapeutic targets for CC.Materials and methods
Histologically and clinically well documented CC cases
were identified and retrieved from our institutional ar-
chive. The inclusion criteria included: 1. diagnosis of
cholangiocarcinoma could be confirmed by review of the
slides; 2. A primary tumor must clinically and patho-
logically arise within the hepatobiliary system, 3. patient
had no past and current history of tumors in other sys-
tem, 4. It was a resection specimen and had at least 3
blocks with carcinoma available for immunohistoche-
mical (IHC) stains; 5. It had both CC and nearby NBD
present on the same slide (A control H&E slide was
made to confirm this, after being cut for IHC stains).
The IHC protocol and related antibodies have been
described before [12]. Briefly, the IHC stains of M2A
antigen (clone D2-40, 1:25, Signet Laboratories, Dedham,
MA), WT1 (clone 6F-H2, 1:400, DakoCytomation,
Carpinteria, CA), calretinin (DC8, 1:50, Zymed La-
boratories, South San Francisco, CA), and cytokera-
tin 5/6 (clone D5/16 B4, 1:25, DakoCytomation) and
CK19 (clone b170, 1:100, Leica/Novocastra) were con-
ducted on formalin fixed paraffin embedded tissue sec-
tions with standard IHC protocols (BondMax, Leica
Microsystem, Buffalo Grove, IL) on 2–3 blocks of each
case. Appropriate positive and negative controls were per-
formed and validated.
The protein expression levels were independently as-
sessed by two of the authors (LZ and RF). When a dis-
agreement was present, the two would have a discussion,
consult with the senior author (PJZ) and reach an agree-
ment upon re-review of the case. A scoring scale of 0–3
was used, with 0 for negative, 1+ for <25%, 2+ for 26-
75%, and 3+ for >75%. The staining intensity was not
considered for the purpose of scoring the stains. The lit-
erature search for related IHC markers’ positive rates
was performed by using the marker’s names and tumors
as the search term in Pubmed (NCBI, NIH, USA) in
Feb. 2014.The statistical analyses were performed by using Stata
(version 11, StataCorp LP). The 95% confidence intervals
(CI) were calculated by using normal distribution. Pearson
Chi-square test was used to determine the association
between IHC markers and tissue samples, so was Fisher
exact test as a confirmation for groups with case number
fewer than 6. All of the P values were calculated for
2-sided. A P value less than 5% was considered statis-
tically significant.
Results
A total of 30 CC cases (10 extrahepatic and 20 intrahe-
patic) with nearby NBD met the inclusion criteria and
were included in this retrospective study. They were col-
lected between 2005 and 2011. The stained slides from
the 2 to 3 blocks of each case all showed similar IHC
staining pattern for each marker evaluated. The IHC
stains for D2-40 and CK5/6 were performed on all of
the 30 cases, and for calretinin, CK19 and WT-1 on 23
of the 30 cases due to the difficulty in obtaining add-
itional blank slides after the dropped tissue sections in
the first 2 IHC attempts. As shown in Table 1, the CC
and NBD of all cases (23/23, 100% for both) were posi-
tive for CK19, a known pancreatobiliary marker. All CC
and NBD were negative for WT-1 and D2-40, both
known as mesothelial markers, except 1 NBD positive
for WT-1 (1/23, 4.3%) and 1 CC positive for D2-40 (1/30,
3.3%). Those unexpected positive WT-1 and D2-40 stains
were focal, and scored only 1+ (less than 25%, see Table 2).
No significant difference of CK19, WT-1 or D2-40
IHC stain was found between the CC and NBD groups
(Tables 1 and 2).
Of the 23 CC cases evaluated for calretinin positivity,
12 (52.2%, 95% CI 30.6-73.2%) were stained positive. CC
tumor cells of the 12 cases showed dense and diffuse
nuclear and cytoplasmic staining pattern of calretinin
(Figure 1), while negative in the adjacent NBD in all
cases (P < 0.001). For CK5/6 evaluation, 22 (73%) of
CC and all 30 (100%) of NBD were positive (Table 2,
Figure 2). Comparison of the CK5/6 expression in CC
and the adjacent NBD revealed CC stained weaker than
NBD in 18 (60.0%) cases, similar to NBD in 10 (33.3%),
and stronger than NBD in 2 (6.67%) (Tables 2 and 3).
Eight out of the 30 CC cases (26.7%, 95% CI 12.3-45.9%)
were stained negative for CK5/6 while none of the NBD
was negative (P = 0.002). The difference of CK5/6 in CC
versus adjacent NBD is statistically significant (P = 0.022,
Table 3). Of note, the two cases with CC stained stronger
than NBD had 3+ stains in CC and 2+ in NBD (25–50
staining area difference). In the meantime, 9 (50%) of the
18 cases with CC stained weaker than NBD presented a
difference of 2+ or more (50-99%) (Table 3).
We then sought the best IHC diagnostic criteria for
differentiating CC versus NBD by comparing various





Total, n (%) P value* P value#
Calretinin CC 11 (47.8, 26.8-69.4) 12 (52.2, 30.6-73.2) 23 (100) <0.001 NA
NBD 23 (100, 85.2-100^) 0 (0) 23 (100)
WT1 CC 23 (100, 85.2-100^) 0 (0) 23 (100) 0.312 1
NBD 22 (95.6, 78.1-99.9) 1 (4.3, 0.1-21.9) 23 (100)
D2-40 CC 29 (96.7, 82.8-99.9) 1 (3.3, 0–17.2) 30 (100) 0.313 1
NBD 30 (100, 88.4-100^) 0 (0) 30 (100)
CK19 CC 0 (0) 23 (100, 85.2-100^) 23 (100) 0.312 NA
NBD 0 (0) 23 (100, 85.2-100^) 23 (100)
CK5/6 CC 8 (26.7, 12.3-45.9) 22 (73.3, 54.1 -87.7) 30 (100) 0.002 NA
NBD 0 (0) 30 (100, 88.4-100^) 30 (100)
Note: CC: Cholangiocarcinoma, NBD: accompanying normal bile duct, NA: not applicable, *comparison between CC and NBD by using Pearson Chi-square test,
#comparison between CC and NBD by by using Fischer’s exact test, ^one-sided, 97.5% confidence interval.
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tivity of 69.59% was achieved by using the sequential
stains of calretin and CK5/6, with positive calretinin and
negative CK5/6 in the calretinin negative cases as the
positive result for CC (sequential calretinin and CK5/6
criteria), while maintaining 100% specificity. This sensi-
tivity was statistically higher than that of calcretinin stain
more than 2+, or negative CK5/6 stain. However, we did
not find the sensitivity difference between the sequential
calretinin and CK5/6 criteria and the others, including
positive calretinin stain alone (52.17%), CK5/6 stained
negative or 1+ (60.0%) and less CK5/6 stain in CC than
NBD (56.67%) (Table 4). Our Fisher exact test also re-
vealed that CK5/6 expression was more likely associated
with well-differentiated CC and extrahepatic CC, but no
association between the calretinin expression and the
CC grade or location (Table 5).
Discussion
Cholangiocarcinoma is an uncommon carcinoma in the
developed countries, but had a rising mortality in both
UK and USA [1,2]. Its carcinogenesis and diagnostic
markers are not well defined. Studies have revealed some
IHC markers such as CK7, CK19, MOC31, claudin4,
HMGA, CD133 and Annexin A1, but with variableTable 2 Immunohistochemical stain scores of the cholangioca
Calretinin, n (%) WT1, n (%) D2-4
CC NBD CC NBD CC
Negative 11 (47.8) 23 (100) 23 (100) 22 (95.6) 29 (9
1+ 4 (30.8) 0 (0) 0 (0) 1 (4.3) 1 (3.
2+ 4 (30.8) 0 (0) 0 (0) 0 (0) 0 (0)
3+ 4 (30.8) 0 (0) 0 (0) 0 (0) 0 (0)
All Positive 12 (52.2) 0 (0) 0 (0) 1 (4.3) 1 (3.
total 23 (100) 23 (100) 23 (100) 23 (100) 30 (1
Note: CC: Cholangiocarcinoma, NBD: accompanying normal bile duct.specificities (Table 6) [3-5,13]. In particular, little is
known about the IHC marks’ expression in NBD. To
our best knowledge, this study is the first to explore the
use of a set of known mesothelial markers for differenti-
ating CC from accompanying NBD.
Calretinin is a 29–30 kilodalton calcium binding pro-
tein primarily expressed in the nerves [33]. Since it was
found expressed in mesothelioma in 1990s [34], many
types of tumor and tissue are found immunocreactive to
calretinin including 22.5% of examined colonic carcin-
omas [35], 81.5% of ameloblastomas [36], 36% of thymic
carcinomas [10], 100% of cardiac myxomas [37], 56-100%
sex cord-stromal and 90-100% fibrous neoplasms of the
ovaries [38-40], 95% olfactory neuroblastoma [41], 95% of
adrenal cortical tumors [42], 71% of synovial sarcomas
[43], 15% breast carcinomas [44], skin [45] and others
[46]. Our study indicates that CC may be calretinin posi-
tive regardless of CC grade and location, and should be
considered in the differential diagnoses for calretinin po-
sitive tumor. As many as 52% of our CC cases showed
strong nuclear and cytoplasmic calretinin expression,
while none in the NBD, suggesting a potential role of
calretinin in differentiating CC from NBD and in CC
carcinogenesis (Table 4). In contrast, CK19 positivity does
not discriminate CC and non-cancerous NBD, and shouldrcinoma and accompanying normal bile ducts
0, n (%) CK19, n (%) CK5/6, n (%)
NBD CC NBD CC NBD
6.7) 30 (100) 0 (0) 0 (0) 8 (26.7) 0 (0)
3) 0 (0) 0 (0) 0 (0) 10 (33.3) 8 (26.7)
0 (0) 1 (4.3) 0 (0) 4 (13.3) 7 (23.3)
0 (0) 22 (95.6) 23 (100) 8 (26.7) 15 (50)
3) 0 (0) 23 (100) 23 (100) 22 (73.3) 30 (100)
00) 30 (100) 23 (100) 23 (100) 30 (100) 30 (100)
Figure 1 A case showed nuclear and cytoplasmic calretinin
reaction in CC (A: H&E, B&C: calretinin ×40& ×200), and a
negative cytoplasmic stain in NBD (D: calretinin ×200).
Table 3 Comparison of CK5/6 stains between
cholangiocarinoma and normal bile duct
CC
NBD 0 1 2 3
0
1 3 4
2 3 2 2
3 2 4 4 6
Note: Stain intensity comparison: CC < NBD: 18, CC = NBD: 10, and CC > NBD: 2
(P = 0.022); CC: Cholangiocarcinoma, NBD: accompanying normal bile duct. The
number in bold shows the case number with stain difference of more than 1+
(>25% difference).
Zhang et al. Experimental Hematology & Oncology 2014, 3:12 Page 4 of 8
http://www.ehoonline.org/content/3/1/12be used only for confirmation of a bile duct (biliary)
lineage.
We also examined the expression of other mesothelial
markers in CC and NBD including WT1, D2-40 and
CK5/6 [12,30,47-49]. Not surprisingly, our data showed
that WT1 and D2-40 remained highly specific for meso-
thelial lineage, and should be included in the panel to
differentiate mesothelioma from CC. Of note, WT1 has
also been reported positive in more than 90% in adeno-
matoid tumors [50], 76% ovarian sex cord-stromal tu-
mor [39], 77% serous papillary carcinoma of the ovary
[40], and 29% of endometrioid carcinoma [40]. CautionFigure 2 A case showed nuclear and cytoplasmic CK5/6
reaction in CC (A: H&E, B: CK5/6 ×200) and a weaker
cytoplasmic stain in a NBD (C&D: CK5/6 ×40& ×200).therefore should be used when interpreting a WT1 posi-
tive stain, particularly in female patients. Addition of
D2-40 may also improve the sensitivity and specificity
for confirming mesothelial differentiation [12].
CK5/6 is a high molecular-weight cytokeratin highly
expressed in stratified epithelium and mesothelium, first
found useful for distinguishing mesothelioma from ade-
nocarcinoma in late 1990s [51,52]. Its positive rate in
mesothelioma is comparable to that of calretinin [20]. A
recent systemic review also confirms that CK5/6 is one
of the two most sensitive IHC markers (sensitivity of
83%), and one of the two most specific IHC markers
(specificity of 85%) for epitheloid mesothelioma [30].
However, many tumors other than mesothelioma are also
positive for CK5/6, including but not limited to 88% of
adenosquamous carcinoma of the pancreas [53], 55% of
metastatic squamous carcinoma of various origin [54],
75% of lung squamous cell carcinoma in fine needle aspir-
ate specimens [55], 100% of squamous cell carcinoma in
pleural fluids [14], 98% of squamous cell carcinoma and
18% of adenocarcinoma in the lung [56], 62% of urothelial
carcinoma [57], and 50% of endometrial adenocarcinoma
[57]. Our study showed that all NBD and 73.3% of CC
were positive for CK5/6. Further analysis found that
CK5/6 expression was significant lower in the CC than
the accompanying NBD (Table 3). Those findings demon-
strate the differential expressions of CK5/6 in CC and
NBD, and suggest a potential use of CK5/6 in differen-
tiating CC from NBD. The association between CK5/6
expression and extrahepatic and well-differentiated CC in-
dicates a preference of using CK5/6 in those CCs.
Of the markers we tested, the best sensitivity to iden-
tify CC is reached by using sequential criteria of positive
calretinin and negative CK5/6 in the calretinin negative
cases, with a 100% specificity. Using positive calretinin
stain criterion is straight forward, and will result in only
a 17.47% loss of sensitivity, or missing 4 out of 23 cases
as shown in our study. This may be the second best
strategy of using calretinin and/or CK5/6 to differentiate
CC from NBD. The criterion of less CK5/6 stain in tumor
than NBD requires presence of both tumor and NBD in
Table 4 Comparison of various calretinin and CK5/6 diagnostic criteria for cholangiocarcinoma
No. Criteria CC Total CC Sensitivity P value* NBD Total NBD Specificity P value*
1 Cal 1+ 12 23 52.17% 0.227 23 23 100.00% NA
2 Cal 2+ 8 23 34.78% 0.018 23 23 100.00% NA
3 Cal 3+ 4 23 17.39% <0.001# 23 23 100.00% NA
4 CK5/6 - 8 30 26.67% 0.002 30 30 100.00% NA
5 CK5/6 - or 1+ 18 30 60.00% 0.472 22 30 73.33% 0.007
6 Less CK5/6 staining in CC than in NBD 17 30 56.67% 0.337 NA
7 Cal+, and CK5/6 - in Cal - cases 16 23 69.57% 23 23 100.00%
Note: Cal: calretinin, CC: Cholangiocarcinoma, NBD: accompanying normal bile duct, NA: not applicable, *Comparison between criteria 7 and other criteria by
using Pearson Chi-square test, #Comparison between criteria 7 and 5 by using Fischer’s exact test.
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ging in core biopsies and cytology specimens. We there-
fore doubt its clinical usefulness due to specimen type
limitations. Negative or 1+ CK5/6 stain gave us the second
highest sensitivity, but also led to a significantly lower spe-
cificity (100% vs 73.3%, P = 0.007). Despite its single IHC
stain requirement, we felt the lower specificity would be a
serious concern for its clinical use. Together, we recom-
mend sequential staining pattern of positive calretinin and
negative CK5/6 in the calretinin negative cases for differ-
entiating CC from NBD. Future work may focus on
larger-scale studies and differentiating CC from HCC and
mesothelioma by using these criteria.
We summarized the expression profiles of the com-
mon IHC markers for CC, mesothelioma and HCC in
Table 6. Interestingly, the positive rates of those markers
vary among studies. For example, the positive rate of
MOC31 in mesothelioma ranged from 8% to 35%. Con-
sistent with our summary, an excellent review and an-
other guidelines have confirmed such a variation amongTable 5 Association of the cholangiocarcinoma grades and lo
Calretintin Calretinin
Neg 1+ 2+ 3+ P Neg Pos Sum P N
WD 3 1 2 1 # 3 4 7 # 0
% 42.86 14.29 28.57 14.29 43 57.1 100 0
MD 6 2 2 0 6 4 10 7
% 60 20 20 0 60 40 100 5
PD 2 1 0 3 2 4 6 1
% 33.33 16.67 0 50 33 66.7 100 1
EH 3 0 3 1 # 3 4 7 # 0
% 42.86 0 42.86 14.29 43 57.1 100 0
IH 8 4 1 3 8 8 16 8
% 50 25 6.25 18.75 50 50 100 4
Sum 11 4 4 4 11 12 23 8
% 47.83 17.39 17.39 17.39 48 52.2 100 2
Notes: WD = well-differentiated, MD =moderately-differentiated, PD = Poorly-differe
cholangiocarcinoma, P: P-value, #: P > 0.005.reports, and made the practical yet useful recommenda-
tions on how to best utilize those markers [15,48,58].
We suggest to include at least WT1 and D2-40 in the
panel to confirm a mesothelial lineage, with optional
addition of calretinin, CK5/6 and/or mesothelin. Should
WT1 and/or D2-40 stain be not interpretable due to
technical issues or limitations (such as a fallen section),
one must use other mesothelial markers to rule out the
tumors with calretinin and CK5/6 reactivity from meso-
thelioma, such as CC as shown in this study. The re-
ported different positive rates of the IHC markers may
be in part attributed to the various IHC staining me-
thods. For example, we noticed that CK5/6 expression
was present in 2% of lung adenocarcinoma by using 1:25
dilution of D5/16B4 antibody (Boehringer-Mannheim)
and Envision + biotin free detection system in Dako
AutoStainer [16], but 39% by using the same 1:25 dilution
of different D5/16B4 antibody (Dako) and Envision +HRP
detection system in the same IHC stainer [12]. Similarly,
using different dilutions of calretinin antibody (rabbit,cations with calrectinin and CK5/6 expression
CK 5/6 CK5/6
eg 1+ 2+ 3+ P Neg Pos Sum P
2 3 2 0.032 0 7 7 0.019
28.57 42.86 28.57 0 100 100
4 0 2 7 6 13
3.85 30.77 0 15.38 53.85 46.15 100
4 1 4 1 9 10
0 40 10 40 10 90 100
4 0 6 0.004 0 10 10 0.029
40 0 60 0 100 100
6 4 2 8 12 20
0 30 20 10 40 60 100
10 4 8 8 22 30
6.67 33.33 13.33 26.67 26.67 73.33 100
ntiated, EH = extrahepatic cholangiocarcinoma, IH = intrahepatic
Table 6 Positive rates of immunohistochemical markers for mesothelioma, cholangiocarcinoma, lung adenocarcinoma
and hepatocellular carcinoma
Mesothelioma (all subtypes included) Cholangiocarcinoma Lung adenocarcinoma Hepatocellular carcinoma
WT-1 43-93% [11,12,14-17] 0%# 0-7% [12,14,16] NA
D2-40 86-100% [12,18,19] 3%# 0-33% [12,18,19] NA
Calretinin 92.4-100% [11,12,16,17,20,21] 52%# 8-23% [12,16,22] NA
CK5/6 64-100% [11,12,15-17,20] 0-73.3%#, [23] 0-39% [12,14-16,23] NA
Mesothelin 47-100% [14,16,17] 33% [7] 38-100% [14,16,22] NA
CK19 NA 89-100#, [3,24] NA 2-10.1% [3,24]
Annexin A1 NA 94.1% [5] NA 0% [5]
Glypican-3 NA 6-7% [3,24] 3.6-9.6% [25,26] 69-87.1% [3,24-26]
Arginase NA 0% [24] 0% [26] 94-95% [24,26]
TTF-1 0% [16] 0-10% [23,27] (nuclear) 20-74% [16,23] (cytoplasmic) 50-93% [27-29]
HepPar-1 NA 0-7% [23,24] 8.1% [26] 74-100% [23,24,26]
MOC31 8-35% [14,16] 88.2% [3] 92-100% [14,16,17,30] 34.0% [3]
EMA 79-93% [16,21] 100% [31,32] 100% [16] 12.5-23% [31,32]
BG 8 7% [16] NA 95-96% [16,17] NA
BerEP4 16-18% [16,21] 100% [23] 74-100% [16,17] 33% [23]
Note: #indicates this study; Sensitivity reported in some studies [17] is included; NA: No IHC data on the respective marker are identified by searching the
Pubmed database.
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ferent calretinin positive rates in lung adenocarcinoma
(8% versus 23%) [11,12,16]. Another study also showed
that the TTF-1 positive rates in hepatocellular carcinomas
vary from 0% to 70% depending on the antibody manufac-
turer [28]. An in-house validation of new antibodies on
various tumors seems a reasonable safe-guard approach
and is recommended.
On the cancer biology level, calretinin has higher posi-
tive rates in CC than mesothelin (52.17% versus 33%),
and may also be a more sensitive and/or specific thera-
peutic target for CC. However, little is known regarding
the roles of calrectin and CK5/6 in the carcinogenesis of
CC and the biology of biliary epithelium. Given the re-
cent identification of both mesothelial progenitor cells
and liver stem cells [59-62], we hypothesize that the
expression of calretinin and CK5/6 in CC is an aber-
rant differentiation of liver/bile duct stem cells, or sim-
ply reflecting the partial mesothelial phenotype of the
NBD. However, much research is needed to examine
our hypothesis.
This study has several limitations. First, this retrospec-
tive study may have selection bias and moderate statis-
tical power. Second, the calretinin and CK5/6 staining
profiles were not compared between CC, mesothelioma
and HCC. A direct comparison of calretinin and CK5/6
expression in those tumors would be more evidential.
Third, the calretinin and CK5/6 IHC patterns in ductal
proliferation including reactive changes or benign ductal
neoplasms were not assessed, but may be of particular
value in differentiating carcinoma and non-cancerouslesions. Last, the prognostic value of calretinin and CK5/
6 expression in CC is not explored in this study, but
may be interesting to investigate because another meso-
thelial marker, mesothelin, has been considered for
therapeutic targets for CC. Survival studies are beyond
the scope of this study, however. Future work is needed
to address the unanswered questions and our study’s
limitations.
Conclusions
In conclusion, we for first time showed calretinin and
CK5/6 expression in CC. The sequential criterion of
positive calretinin stain and negative CK5/6 stain in cal-
retinin negative cases has a sensitivity of 69.57% and a
specificity of 100% for differentiating CC from NBD.
Our data also suggest to include at least one or two
markers more specific for mesothelial differentiation,
such as D2-40 and WT1, in the panel to define a meso-
thelial lineage.
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